Institutional members access full text with Ovid®

Share this article on:

Disseminated Histoplasmosis Responsive to Trimethoprim-Sulfamethoxazole in an AIDS Patient

Bush, Larry M. MD, FACP*†; Palraj, Bharath MD†‡; Chaparro-Rojas, Fredy MD†‡; Perez, Maria T. MD, FCAP§

Infectious Diseases in Clinical Practice: July 2010 - Volume 18 - Issue 4 - pp 239-242
doi: 10.1097/IPC.0b013e3181d65653
Review Articles

HIV-infected individuals living in or having come from geographic areas endemic for Histoplasma capsulatum are at increased risk of developing a disseminated progressive form of infection (disseminated progressive histoplasmosis or DPH) with this fungus. The degree of immunosuppression, particularly as related to the absolute CD4 T-cell lymphocyte count, correlates to the incidence and severity of disease caused by this endemic fungus. The diagnosis, which relies on culture, histopathology, or radioimmunoassay antigen detection, presents clinical similarities with other opportunistic infection pathogens. Recent published guidelines recommend initial therapy with liposomal amphotericin B, followed by itraconazole, for at least 12 months and perhaps longer. We describe a case of DPH in a newly diagnosed AIDS patient who demonstrated significant clinical, laboratory, and imaging improvement during treatment with trimethoprim-sulfamethoxazole alone. A propos this case, we review DPH and the published literature addressing the effectiveness of trimethoprim-sulfamethoxazole as a treatment option, suggesting its consideration for inclusion in future trials.

From the *University of Miami-School of Medicine at Florida Atlantic University, Boca Raton; †Division of Infectious Diseases, Department of Medicine, JFK Medical Center, Palm Beach County; ‡University of Miami-Miller School of Medicine at Florida Atlantic University, Boca Raton; and §Department of Laboratory and Pathology Medicine; WellingtonRegional Medical Center, Palm Beach County, FL.

Reprints: Larry M. Bush, MD, FACP, Atlantis Medical Center, 5503 South Congress Ave, Suite 104, Atlantis, FL 33462. E-mail: drlarry561@aol.com.

The authors have no funding or conflicts of interest to disclose.

© 2010 Lippincott Williams & Wilkins, Inc.